Status:
ENROLLING_BY_INVITATION
Development of a Patient-reported Outcome Measure for Women With Chronic Pelvic Pain
Lead Sponsor:
Weill Medical College of Cornell University
Collaborating Sponsors:
Society of Interventional Radiology Foundation
Evidera
Conditions:
Chronic Pelvic Pain Syndrome
Pelvic Congestive Syndrome
Eligibility:
FEMALE
18-60 years
Brief Summary
The purpose of this study is to develop a patient questionnaire that can be utilized to assess the benefit of treatments of chronic pelvic pain in research studies. The information collected from a s...
Detailed Description
The purpose of this study is to develop a patient-reported outcome (PRO) instrument that can be utilized as an efficacy endpoint to assess medical and surgical treatments of chronic pelvic pain (CPP) ...
Eligibility Criteria
Inclusion
- I. First phase of study evaluation women with presumed venous origin chronic pelvic pain
- Inclusion Criteria :
- Non-menopausal women ≥18 years old.
- a. Women who are not menstruating because of ovarian suppression therapy for CPP are eligible.
- CPP meeting the American College of Obstetricians and Gynecologists criteria.
- Patient pain is primarily of pelvic and/or pelvic floor origin. Patient may experience other pain symptoms, including bowel, bladder, musculoskeletal, skin allodynia and hyperalgesia, or lower extremity venous or vulvar pain.
- Imaging demonstrating multiple tortuous pelvic varicose veins \> 5 mm in diameter in the ovarian, utero vaginal, and/or uterine arcuate venous plexus.
- a. Imaging must be documented from trans vaginal ultrasound, trans abdominal ultrasound, magnetic resonance imaging, computed tomography, catheter venogram, or trans fundal pelvic venogram. If laparoscopic images are available to confirm veins this size, this would be acceptable as well.
- Venous contribution to CPP, as determined by clinical impression from a CPP specialist. Clinical impression will be based on the presence of the following symptoms and physical findings:
- a. Symptoms: i. CPP increased with standing, walking, or lifting ii. CPP increased at the end of the day iii. CPP improved by laying down iv. Sexually provoked prolonged post-coital ache b. Physical findings: i. Adnexal tenderness on gentle bimanual exam ii. Tenderness at the ovarian point trans-abdominally iii. Tenderness of the uterus
- Participant can read, communicate clearly, and understand English or Spanish.
- Participant is willing and able to participate in an interview and complete questionnaires.
- Participant is willing and able to provide informed consent.
- Exclusion Criteria:
- Pain symptoms should primarily be of pelvic and/or pelvic floor origin (inclusion criteria #3 above). Pain should not be exclusively low back, hips, symphysis, allodynia or hyperalgesia of the skin, or from varicose veins of the vulvar and/or lower extremities.
- Pain thought primarily to be due to endometriosis, pelvic floor myalgia, a musculoskeletal etiology, irritable bowel disease, or painful bladder syndrome/interstitial cystitis.
- Obvious endometriosis based on physical exam or laparoscopy findings.
- Patients previously treated with a technically successful surgery or vascular procedure for a venous disorder of the pelvis or renal vein.
- Participant has any clinically relevant medical condition (e.g., severe co morbid condition, severe mental illness, severe visual or auditory impairment, or cognitive impairment) that, in the opinion of the investigator, would interfere with participating in an interview and/or completing the study procedures
- II. Second phase of study evaluation women with non-venous origin chronic pelvic pain
- Inclusion Criteria :
- Non-menopausal women ≥18 years old.
- a. Women who are not menstruating because of ovarian suppression therapy for CPP are eligible.
- CPP meeting the American College of Obstetricians and Gynecologists criteria.
- Patient pain is primarily of pelvic and/or pelvic floor origin. Patient may experience other pain symptoms, including bowel, bladder, musculoskeletal, skin allodynia and hyperalgesia, or lower extremity venous or vulvar pain.
- Imaging demonstrating multiple tortuous pelvic varicose veins \> 5 mm in diameter in the ovarian, utero vaginal, and/or uterine arcuate venous plexus.
- a. Imaging must be documented from trans vaginal ultrasound, trans abdominal ultrasound, magnetic resonance imaging, computed tomography, catheter venogram, or trans fundal pelvic venogram. If laparoscopic images are available to confirm veins this size, this would be acceptable as well.
- Venous contribution to CPP, as determined by clinical impression from a CPP specialist. Clinical impression will be based on the presence of the following symptoms and physical findings:
- a. Symptoms: i. CPP increased with standing, walking, or lifting ii. CPP increased at the end of the day iii. CPP improved by laying down iv. Sexually provoked prolonged post-coital ache b. Physical findings: i. Adnexal tenderness on gentle bimanual exam ii. Tenderness at the ovarian point trans-abdominally iii. Tenderness of the uterus
- Participant can read, communicate clearly, and understand English or Spanish.
- Participant is willing and able to participate in an interview and complete questionnaires.
- Participant is willing and able to provide informed consent.
- Exclusion Criteria:
- Pain symptoms should primarily be of pelvic and/or pelvic floor origin (inclusion criteria #3 above). Pain should not be exclusively low back, hips, symphysis, allodynia or hyperalgesia of the skin, or from varicose veins of the vulvar and/or lower extremities.
- Pain thought primarily to be due to endometriosis, pelvic floor myalgia, a musculoskeletal etiology, irritable bowel disease, or painful bladder syndrome/interstitial cystitis.
- Obvious endometriosis based on physical exam or laparoscopy findings.
- Patients previously treated with a technically successful surgery or vascular procedure for a venous disorder of the pelvis or renal vein.
- Participant has any clinically relevant medical condition (e.g., severe co morbid condition, severe mental illness, severe visual or auditory impairment, or cognitive impairment) that, in the opinion of the investigator, would interfere with participating in an interview and/or completing the study procedures
Exclusion
Key Trial Info
Start Date :
July 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT06083597
Start Date
July 1 2023
End Date
December 31 2026
Last Update
December 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Weill Cornell Medicine
New York, New York, United States, 10065